Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Highly efficient CD8 T cells are associated with natural HIV control, but it has remained unclear how these cells are generated and maintained. We have used a macaque model of spontaneous SIVmac251 control to monitor the development of efficient CD8 T cell responses. Our results show that SIV-specific CD8 T cells emerge during primary infection in all animals. The ability of CD8 T cells to suppress SIV is suboptimal in the acute phase but increases progressively in controller macaques before the establishment of sustained low-level viremia. Controller macaques develop optimal memory-like SIV-specific CD8 T cells early after infection. In contrast, a persistently skewed differentiation phenotype characterizes memory SIV-specific CD8 T cells in non-controller macaques. Accordingly, the phenotype of SIV-specific CD8 T cells defined early after infection appears to favor the development of protective immunity in controllers, whereas SIV-specific CD8 T cells in non-controllers fail to gain antiviral potency, feasibly as a consequence of early defects imprinted in the memory pool.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2020.108174DOI Listing

Publication Analysis

Top Keywords

cd8 t cells
28
siv-specific cd8
20
cd8
9
primary infection
8
associated natural
8
efficient cd8
8
controller macaques
8
early infection
8
t cells
7
siv-specific
5

Similar Publications

Mandatory preventive vaccines for infectious diseases expressing T-cell epitopes for cancer prevention.

Infect Agent Cancer

July 2025

Innovative Immunological Models Unit, Istituto Nazionale Tumori - IRCCS - "Fond G. Pascale", Via Mariano Semmola, 52, Naples, Italy.

We have previously reported that microorganism-associated antigens (MAAs) share high sequence and conformational homology with tumor-associated antigens (TAAs) as well as T cells cross-react with homologous MAA/TAA pairs. More recently, we have also shown that the SARS-CoV-2 preventive vaccine, besides the humoral response, is able to elicit also a T cell response which cross-react with homologous TAAs. In the present study we analyzed the mandatory pediatric vaccines, namely the hexavalent vaccine (Diphtheria, Tetanus, Pertussis (whooping cough), Polio, Haemophilus influenzae type b (Hib), Hepatitis B) and the MMR (measles, mumps and rubella), and the chickenpox vaccine.

View Article and Find Full Text PDF

Background: Cancer immunotherapy includes vaccines generated through distinct approaches, each with advantages and limitations. Those made of autologous or allogeneic whole cells do not require prior identification of antigens, that is, immunize against undetermined (agnostic) tumor antigens. However, they often exhibit low adjuvanticity and modest antigenicity.

View Article and Find Full Text PDF

Introduction: Benign prostatic hyperplasia (BPH) is among the most common age-associated diseases in men. Prostatic immune cell infiltration is frequently observed with aging coincident with BPH; however, the contribution of age-related changes in immune cells to BPH is not clear. As T cells are the predominate immune cell in aged prostates, it is hypothesized that age-associated alterations in T cell subsets contribute to BPH symptoms.

View Article and Find Full Text PDF

Multipath ROS Storm and Immune Activation via Sulfur Vacancy-Optimized ZnInS Nanosheets for Piezocatalytic Tumor Therapy.

Angew Chem Int Ed Engl

August 2025

State Key Laboratory of Rare Earth Resource Utilization, Changchun Institute of Applied Chemistry, Chinese Academy of Sciences, Changchun, 130022, P.R. China.

Piezocatalytic therapy is a novel therapeutic strategy that uses mechanical energy to drive catalytic reactions to generate cytotoxic reactive oxygen species (ROS). However, existing materials are limited by low intrinsic catalytic efficiency and a single route to ROS production. This makes it difficult to break through the antioxidant barrier of the tumor microenvironment, which severely limits the antitumor efficacy.

View Article and Find Full Text PDF

Aim: The effectiveness of immunotherapy with tumor associated antigen vaccines can be enhanced by combining oncolytic viruses with immune checkpoint inhibitors. This study evaluates the efficacy of oncolytic reovirus in combination with an adenovector expressing carcinoembryonic antigen (Ad-CEA) and a programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitor in a mouse model.

Methods: Mice bearing CEA-expressing CT26 tumor cells were immunized with Ad-CEA along with a PD-1/PD-L1 inhibitor.

View Article and Find Full Text PDF